Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 2Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Oligodendroglioma 1Glioblastoma 1Astrocytoma 1

Interventions

Cyclophosphamide 391Carboplatin 345pembrolizumab 332Gemcitabine 332Cisplatin 328Paclitaxel 298Radiotherapy 297Docetaxel 288Bevacizumab 254Rituximab 234Capecitabine 224Nivolumab 222Dexamethasone 206Fluorouracil 191fludarabine 178Oxaliplatin 178Pemetrexed 154Doxorubicin 153Irinotecan 149Leucovorin 145Etoposide 144Cytarabine 134Cetuximab 131fludarabine phosphate 129Bortezomib 129Lenalidomide 126Erlotinib Hydrochloride 121Filgrastim 120Temozolomide 113Radiosurgery 113

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × talampanel × Clear all
NCT00062504 2011-05-23

Phase 2 Trial Using Talampanel in Patients With Recurrent High Grade Gliomas

Teva Branded Pharmaceutical Products R&D, Inc.

Phase 2 Terminated
30 enrolled
CNS

Astrocytoma, Glioblastoma, Oligodendroglioma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡